Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) II - Antilipolytic and blood lipid lowering activity.
D000375:Aging; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D000960:Hypolipidemic Agents; D008055:Lipids / Q000097:blood*; D008066:Lipolysis / Q000187:drug effects*; D008099:Liver / Q000378:metabolism; D051379:Mice; D009539:Nicotinic Acids / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D014280:Triglycerides / Q000378:metabolism
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D008055:Lipids; D009539:Nicotinic Acids; D011719:Pyrazines; D014280:Triglycerides; D002784:Cholesterol; C027696:acipimox